share_log

S-1/A: General form for registration of securities under the Securities Act of 1933 (Amendment)

S-1/A: General form for registration of securities under the Securities Act of 1933 (Amendment)

S-1/A：證券上市註冊聲明(修正)
美股SEC公告 ·  09/13 05:14
牛牛AI助理已提取核心訊息
180 Life Sciences Corp. has announced an offering of up to 3,296,703 shares of common stock, pre-funded warrants to purchase an equivalent number of shares, and common warrants to purchase up to the same number of shares. The pre-funded warrants have an exercise price of $0.0001 per share and are immediately exercisable. The common warrants have an assumed initial exercise price of $1.82 per share, equal to the last reported sales price of the company's common stock on Nasdaq as of September 10, 2024. These common warrants will be exercisable upon obtaining stockholder approval or immediately if certain pricing conditions are met. The offering is being conducted on a 'reasonable best efforts' basis by A.G.P./Alliance Global Partners as the sole placement agent. The company intends to use the net proceeds for research and development expenses, transaction costs to complete a strategic transaction, legal expenses, and working capital. The offering is expected to close on or about the date of the prospectus, subject to customary closing conditions.
180 Life Sciences Corp. has announced an offering of up to 3,296,703 shares of common stock, pre-funded warrants to purchase an equivalent number of shares, and common warrants to purchase up to the same number of shares. The pre-funded warrants have an exercise price of $0.0001 per share and are immediately exercisable. The common warrants have an assumed initial exercise price of $1.82 per share, equal to the last reported sales price of the company's common stock on Nasdaq as of September 10, 2024. These common warrants will be exercisable upon obtaining stockholder approval or immediately if certain pricing conditions are met. The offering is being conducted on a 'reasonable best efforts' basis by A.G.P./Alliance Global Partners as the sole placement agent. The company intends to use the net proceeds for research and development expenses, transaction costs to complete a strategic transaction, legal expenses, and working capital. The offering is expected to close on or about the date of the prospectus, subject to customary closing conditions.
180 Life Sciences Corp. 宣佈發行高達3,296,703股普通股、可預先融資的購股權證以購買相等數量的股份和普通股權證以購買高達相同數量的股份。可預先融資的購股權證的行權價格爲每股0.0001美元，並且可以立即行使。普通股權證的假設初始行權價格爲每股1.82美元，與2024年9月10日納斯達克公司普通股的最後報價相等。這些普通股權證將在獲得股東批准後行使，或者在滿足某些定價條件時立即行使。這次發行由A.G.P./全球夥伴作爲唯一的委託代理商以「合理最大努力」的方式進行。該公司打算將募集的淨收益用於研究和開發費用、完成戰略交易的交易費用、法律費用和營運資金。該發行預計將於招股說明書的日期前後關閉，視常規結束條件而定。
180 Life Sciences Corp. 宣佈發行高達3,296,703股普通股、可預先融資的購股權證以購買相等數量的股份和普通股權證以購買高達相同數量的股份。可預先融資的購股權證的行權價格爲每股0.0001美元，並且可以立即行使。普通股權證的假設初始行權價格爲每股1.82美元，與2024年9月10日納斯達克公司普通股的最後報價相等。這些普通股權證將在獲得股東批准後行使，或者在滿足某些定價條件時立即行使。這次發行由A.G.P./全球夥伴作爲唯一的委託代理商以「合理最大努力」的方式進行。該公司打算將募集的淨收益用於研究和開發費用、完成戰略交易的交易費用、法律費用和營運資金。該發行預計將於招股說明書的日期前後關閉，視常規結束條件而定。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。